A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)

Part of paid clinical trials in Mount Laurel, New Jersey.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05068609
Status
Completed

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Participants in this study are being treated with nivolumab for SCCHN

Study Details

The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among participants treated with nivolumab in a real-world setting.

Key Dates

Start date
Aug 13, 2020
Status verified
May 2022
Primary completion
Oct 18, 2021
Completion
Oct 18, 2021

Study Design

Enrollment
509 participants (actual)

Arms

  • Arm: Cohort 1
    Participants with squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab

Primary Outcome Measure

Distribution of demographic characteristics of R/M SCCHN participants treated with nivolumab: Month and year of birth [ Time Frame: At enrollment ]

Locations (1)

FacilityCityStateZIPSite coordinators
Local InstitutionMount LaurelNew Jersey08054-

Find similar trials in Mount Laurel, NJ

By research site
Local Institution· Mount Laurel, NJ

Related Studies